SITC 2026 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.

This conference will gather immunologists, oncologists, technologists, and engineers from academia and industry focused on basic research and clinical translation with the goal of fostering interactions among stakeholders that do not normally interact. To achieves this the conference program will feature new approaches targeting innate cells, application of model systems that replicate aspects of human cancer to inform new therapeutic approaches, the application of protein engineering and materials science to bridge gaps in treatment along with the latest innovations regarding T cell state regulation and application of checkpoint therapy in the clinic.

Early Registration Deadline: November 23, 2026
Scholarship Deadline: September 29, 2026
Short Talk Abstract Deadline: September 29, 2026
Poster Abstract Deadline: January 4, 2027

The 2027 SITC Spring Scientific will bring together experts in cell therapy, drug development, and immuno-oncology to address the timely topics of next-generation cell therapies, T cell engagers, antibody-based therapies, vaccines and other novel IO modalities. The program will feature in-depth explorations and discussions of recent scientific breakthroughs, the newest clinical studies, and cutting-edge technologies that address the use of novel agents in cancer immunotherapy.

Cochairs

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Wolfgang Wilmanns Stiftung (WWS), the German Cancer Consortium (DKTK), the Central European Cooperative Oncology Group (CECOG), the Chinese American Hematologist and Oncologist Network (CAHON) as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Immunotherapies have shown substantial clinical activity for a subset of patients with cancer. Despite these encouraging results, a large fraction of patients does not respond or fully benefit from current immunotherapies. Most tumours need to evade the immune system in order to thrive. The understanding of how cancer escapes the immune system is crucial to identify novel therapeutic targets and approaches to expand the population of patients that could benefit from immunotherapies. In this meeting, top scientists in the field will present the latest discoveries related to the interaction of the immune system with tumours and show the new advances in immunotherapy with the aim of discussing how these therapies can improve the lives of patients.

Scientific Program Committee:
Joan Seoane (Chair), Spain
Leila Akkari, Netherlands
Alena Gros, Spain
Marcela Maus, USA

The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) brings together international experts to discuss the latest advancements in pediatric immunotherapy. The event will be hosted in-person only to encourage productive interactions.

Program TBD

Program TBD

The field of immuno-oncology has achieved remarkable breakthroughs over the past decade. Yet, many challenges remain—from understanding the biology of resistant tumor types to identifying novel therapeutic targets and strategies. This year’s symposium will showcase cutting-edge research and highlight promising approaches in areas such as immunometabolism, resistance to immunotherapy, in vivo immune engineering, emerging therapeutic modalities, aging and immune dysfunction, cell therapy for AML, and more.

In addition to keynote lectures and plenary talks, the program features industry updates, short talks selected from abstracts, and a panel discussion on moving discoveries from the bench to the clinic. Ample networking opportunities will give participants the chance to connect with peers, collaborators, and leaders shaping the future of cancer immunotherapy.